Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma

NCT07750067 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Metastatic
NRAS Mutation

Interventions

DRUG: Tunlametinib
DRUG: Pucotenlimab
DRUG: Hydroxychloroquine (HC)

Sponsor

Sun Yat-sen University